Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer
Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.
Hope S. Rugo, MD, a professor in the Department of Medicine, Hematology/Oncology, and director, Breast Oncology and Clinical Trials Education at University of California, San Francisco, discusses the updated data from the phase III SOPHIA trial, which compared margetuximab versus trastuzumab (Herceptin) for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.
The SOPHIA trial resulted in a significant improvement in progression-free survival compared with trastuzumab (P = .0006), explains Rugo. Additionally, the response rate and clinical benefit were significantly increased with margetuximab, showing a clinically important difference in response, according to Rugo.
The hazard ratio showed a 24% relative improvement and the absolute difference in overall survival between margetuximab and trastuzumab was 1.3 months. About 70% of planned events have been accumulated with this analysis and there is a non-significant trend towards improved survival with margetuximab.
